← All trials
NCT05855746
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 22, 2024
- Primary completion
- Jul 22, 2024
- Completion date
- Jan 22, 2028
- First posted
- May 11, 2023
- Last posted
- Nov 27, 2023
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Assistance Publique - Hôpitaux de ParisLead sponsor
- Fonds de Dotation ACTIONCollaborator
- University of LyonCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.